Over 3,200 participants joined us in Vienna at AD/PDTM 2017. The scientific program was packed with symposia, poster sessions, expert speakers, forum discussions and plenary lectures.
Review the full AD/PDTM 2017 Program
View the AD/PDTM 2017 Abstract Topics
Access the AD/PDTM 2017 Proceedings in Neurodegenerative Diseases
Watch the AD/PDTM 2017 Forum Discussions
Read the AD/PDTM 2017 Accolades
AD/PDTM 2017 PLENARY SESSIONS
GENE SILENCING THERAPY FOR HUMAN NEURODEGENERATIVE DISEASE
Prof. Don Cleveland, USA
Head, Laboratory for Cell Biology, Ludwig Institute for Cancer Research
Distinguished Professor and Chair, Dept. of Cellular and Molecular Medicine, Univ. of California
San Diego, CA
TRANSMISSION OF Α-SYNUCLEIN STRAINS IN SYNUCLEINOPATHIES
Prof. Virginia Lee, USA
Perelman School of Medicine at the University of Pennsylvania
The John H. Ware 3rd Professor in Alzheimer's Research
Director, Center for Neurodegenerative Disease Research and
Marian S. Ware Alzheimer Program
APOE, SYNAPSES, AND ALZHEIMER'S DISEASE
Prof. Tom Sudhof, USA - 2013 Nobel Prize in Physiology or Medicine
Avram Goldstein Professor, Dept. of Molecular & Cellular Physiology, Stanford University School of Medicine
CURRENT DEVELOPMENTS IN THE TREATMENT OF PARKINSON'S DISEASE – FROM DISEASE MODIFICATION TO PREVENTION?
Prof. Werner Poewe, Austria
Director Department of Neurology, Innsbruck Medical University
STAGING PATHOLOGY WITH PET
Prof. Keith Johnson, USA
Massachusetts General Hospital
BLOOD BRAIN BARRIER DYSFUNCTION, NEURODEGENERATION AND ALZHEIMER'S DISEASE
Prof. Berislav V. Zlokovic, USA
Keck School of Medicine, Zilkha Neurogenetic Institute, University of Southern California
Los Angeles, CA
AD/PDTM 2017 – FORUM DISCUSSIONS
These novel Fora, in WEF-style format, brought together corporate participants, neuroscientists and clinicians with outstanding experience in "hottest" research topics in the field of neurodegeneration to discuss the impact of newest preclinical results and cutting edge clinical findings on understanding and treatment development of neurodegenerative disorders. The objective is to exchange novel insights, challenges and solutions on the joint path forward to defining the future of Alzheimer's and Parkinson's therapeutics.
Each forum at AD/PDTM 2017 was 2 hour moderated discussion with maximum 3 minutes introduction statement from each participant followed by selected questions from the audience submitted through the Ask the Speaker function in the Mobile App, prioritized and introduced to the discussion by the moderator. The forum is also open for journalists from different media, including lay press in and may report on progress made by the leaders in this field.
AD/PDTM 2017 – Ask the Professor
The following experts took part in informal question and answer sessions with participants during the lunch breaks. Be sure to look out for this priceless networking opportunity in the 2019 Program.
Luc Buee, France: TAU-BASED THERAPEUTIC INTERVENTIONS/STRATEGIES
Don Cleveland, USA: GENE SILENCING: THERAPY IN THE NERVOUS SYSTEM
Marc Diamond, USA: PRION MECHANISMS IN NEURODEGENERATION: NEW WAYS TO UNDERSTAND HOW TO DIAGNOSE AND TREAT DISEASE
Christian Haass, Germany: WHAT IS THE BEST TREATMENT STRATEGY AGAINST ALZHEIMER'S DISEASE?
Virginia M.Y. Lee, USA: PROFESSIONAL DEVELOPMENT AND CAREER CHOICES FOR PHDS AND MD/PHD
John Q. Trojanowski, USA: MISFOLDED TAU AND ALPHA-SYNUCLEIN: TRANSMISSIBLE PATHOGENS AND TARGETS FOR THERAPY
Agenta Nordberg, Sweden: MOLECULAR IMAGING IN NEURODEGENERATIVE DISORDERS
Thomas Südhof, USA: TOO MANY MEDICAL TRIALS ARE MOONSHOTS IN THE DARK
Walter Koroshetz, USA: NIH RESEARCH IN PARKINSON'S & ALZHEIMER RELATED DEMENTIAS AS WELL AS THE NIH BRAIN INITIATIVE
Frank LaFerla, USA :BECOMING AN INDEPENDENT SCIENTIST AND SUCCEEDING IN ACADEMIA
Eckhard Mandelkow, Germany: TAU: STRUCTURE, BIOLOGY, PATHOLOGY
Eliezer Masliah, USA: STATUS OF FUNDING FOR ALZHEIMER'S DISEASE AND RELATED DEMENTIAS RESEARCH IN THE USA
Li-Huei Tsai, USA: USING PATTERNED NEURAL ACTIVITY TO MODULATE ALZHEIMER'S DISEASE PATHOLOGY
Bart De Strooper, Belgium: FREE TOPICS DISCUSSION
Edward Koo, USA: WHAT'S CHANGED AFTER WORKING IN AD RESEARCH FOR 30 YEARS?
David Holtzman, USA: CAREER DEVELOPMENT
Jie Shen, USA: SCIENTIFIC RIGOR AND CAREER DEVELOPMENT
Peter St. George-Hyslop, Canada: CELL BIOLOGY OF NEW GENES FOR AD, FTD AND ALS
Cynthia Lemere, USA : ANIMAL MODELS -WHAT ARE THEY GOOD FOR?
Rudolph Tanzi, USA: KEEPING YOUR RESEARCH ORIGINAL
Todd Golde, USA: ADVANCING YOUR CAREER: IT'S NOT JUST ABOUT SCIENCE
John Hardy, United Kingdom: ONLY DO RESEARCH YOU ENJOY
Frédéric Checler, France: GAMMA-SECRETASE-LINKED CLINICAL TRIALS FAILURES: AN AMYLOID CASCADE HYPOTHESIS REBUTTAL OR JUST EXPERIMENTAL PITFALLS UNMASKED?
Reinhold Schmidt, Austria: MR IMAGING IN THE STUDY OF BRAIN AGING AND DEMENTIA
Dennis Selkoe, USA: ALPHA-SYNUCLEIN MULTIMERIZATION; AMYLOID ß-PROTEIN AS A THERAPEUTIC TARGET